RxDoctor Payments Data

Alan Goldfischer, MD

Gastroenterology · Goshen, NYNPI 1518980093

Payments from drug & device makers

$2,432in general payments, 2019–2025

Across 151 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$309
  • Nestle Healthcare Nutrition Inc.$278
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$268
  • Johnson & Johnson$254
  • Pfizer$208
  • Bristol Myers Squibb$146
  • plus $968 from 20 others

What the payments were for

  • Food & beverage$2,40299%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,432 in reported general payments places this provider in the 50th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$357,175
Medicare patients
737
Services billed
1,959

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase31$88,122
XifaxanRifaximin19$79,740
LinzessLinaclotide42$32,764
RelistorMethylnaltrexone Bromide11$24,181
Mesalamine38$20,707
Dexlansoprazole DrDexlansoprazole63$16,787
TrulancePlecanatide14$8,059
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates81$5,073
Omeprazole435$4,295
ErythromycinErythromycin Base14$3,925
SutabSod Sulf/Pot Chloride/Mag Sulf24$3,792
Sucralfate33$3,203
Esomeprazole Magnesium67$2,407
Famotidine299$1,944
Pantoprazole Sodium237$1,699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$309$120,88673 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Relistor, Trulance$268$111,98044 claims
Braintree Laboratories, Inc.Sutab$104$3,79224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Goshen

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →